NCT02632981

Brief Summary

Interleukin-32 (IL-32) is a recently described cytokine that is a strong inducer of pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α. A previous report have reported that Porphyromonas gingivalis-derived LPS significantly up-regulated IL-32 expression compared with the unstimulated cells in monocytes (THP-1 cells). They suggested that IL-32 may contribute to the pathogenesis of periodontal disease. In the present study the investigators hypothesized that IL-32 levels may increase in the gingival crevicular fluid (GCF) and saliva of patients with chronic periodontitis compared with healthy controls and these levels may decrease together with treatment.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
54

participants targeted

Target at P50-P75 for phase_1

Timeline
Completed

Started Jul 2014

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2014

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2015

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2015

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

December 10, 2015

Completed
7 days until next milestone

First Posted

Study publicly available on registry

December 17, 2015

Completed
Last Updated

December 17, 2015

Status Verified

December 1, 2015

Enrollment Period

10 months

First QC Date

December 10, 2015

Last Update Submit

December 16, 2015

Conditions

Keywords

Interleukin-32periodontitis

Outcome Measures

Primary Outcomes (1)

  • Biochemical parameters (IL-32, IL-10 and THF-alpha)

    The changes in levels of IL-32 after periodontal treatment determined by ELISA. The changes in levels of IL-32 were analyzed to determine diagnostic and prognostic potential as a biomarker of periodontitis.

    Baseline and 1 month after treatment

Secondary Outcomes (5)

  • Probing pocket depth

    Baseline and 1 month after treatment

  • Probing pocket depth and clinical attachment level

    Baseline and 1 month after treatment

  • Gingival index

    Baseline and 1 month after treatment

  • Plaque index

    Baseline and 1 month after treatment

  • Bleeding on probing

    Baseline and 1 month after treatment

Study Arms (2)

chronic periodontitis patients

ACTIVE COMPARATOR

gingival crevicular fluid and saliva collecion were taken before and after nonsurgical periodontal treatment

Other: nonsurgical periodontal treatment

periodontally healthy controls

PLACEBO COMPARATOR

gingival crevicular fluid and saliva collection were taken at baseline after oral hygiene instructions

Other: Gingival crevicular fluid and saliva collection

Interventions

Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.

Also known as: chronic periodontitis patients
chronic periodontitis patients

GCF collection with filter paper (Periopaper) using the intracrevicular method. Patients' mouths were rinsed with distilled water, and unstimulated salivary samples were collected by patients expectorating into disposable tubes.

Also known as: periodontally healthy controls, chronic periodontitis patients
periodontally healthy controls

Eligibility Criteria

Age35 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • all subjects in the study were possess of at least 20 teeth excluding third molars.

You may not qualify if:

  • agressive periodontitis,
  • periapical pathologies,
  • excessive forces including mechanical forces caused by orthodontic forces and occlusal forces;
  • presence of systemic diseases;
  • administration of non-steroidal and anti-inflammatory drugs or antibiotic therapies within the previous 6 months;
  • need for antibiotic prophylaxis for dental treatment and having received non-surgical periodontal treatment within the past 6 months or surgical periodontal treatment within the past 12 months;
  • allergy or sensitivity to any drug,
  • pregnancy,
  • lactation, and
  • current and former use of tobacco.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Periodontitis

Condition Hierarchy (Ancestors)

Periodontal DiseasesMouth DiseasesStomatognathic Diseases

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Bülent Ecevit University Faculty of Dentistry

Study Record Dates

First Submitted

December 10, 2015

First Posted

December 17, 2015

Study Start

July 1, 2014

Primary Completion

May 1, 2015

Study Completion

July 1, 2015

Last Updated

December 17, 2015

Record last verified: 2015-12